Pol3 mutation disrupts organ growth

The cellular mechanism that turns DNA into all of the thousands of proteins that make up a human body is itself both intricate and interesting. A key player in the process—called transcription—is the enzyme RNA polymerase III. Work published online this week in the open-access journal PLoS Biology reports that a mutation of this enzyme prevents cell division, but surprisingly, only affects the development of specific organs. It may also have a therapeutic application against cancer.

A team of researchers led by Dr. Michael Pack, at the University of Pennsylvania, investigated the mutation in RNA polymerase III of the zebrafish, an animal model system that is increasingly being used to study human development and disease.

Seventeen different subunits combine to form the RNA polymerase III enzyme in organisms as diverse as yeast, zebrafish, and humans. The mutation they studied, which is called slim jim (because mutant fish are comparatively thin due to developmental differences), affects only one of these subunits. This subtle change is enough to prevent cells from dividing, because with disrupted transcription machinery, a cell is unable to make enough protein to give rise to two daughter cells.

To further study how the slim jim mutation affected the 17 subunit RNA Polymerase III complex, Dr. Pack’s laboratory collaborated with Dr. Richard Maraia. Dr. Maraia’s laboratory, at the National Institutes of Health, engineered a similar mutation in the fission yeast Sacchromyces pombe.

These experiments showed that the mutation’s effect arises because the mutated subunit cannot interact properly with one of its neighbors in the yeast RNA Polymerase III complex. Remarkably, Dr. Pack’s lab showed that when high levels of this interacting subunit are experimentally induced in zebrafish, the slim jim defects were reversed. These experiments are interesting because they show how highly conserved the transcriptional mechanism and its regulation have been throughout animal evolution.

The slim jim mutation only has a strong effect in certain zebrafish tissues, such as the intestine, whereas other organs, including the heart, are relatively unaffected. Dr. Pack explained that this is likely to derive from the different developmental patterns of each organ. Tissues that require cell division to continue late into development or in the adult—and therefore have higher demands for protein production—are the most severely affected.

This provides hope that disrupting this gene in cancer patients may prove beneficial. Cancer is a disease caused by unstoppable cell division, and a therapy that decreases the efficiency of RNA Polymerase III would have a strong effect specifically on cancer growth, which has very high demands for protein production.

Citation: Yee NS,, Gong W, Huang Y, Lorent K, Dolan AC , et al. (2007) Mutation of RNA Pol III subunit rpc2/polr3b leads to deficiency of subunit Rpc11 and disrupts zebrafish digestive development. PLoS Biol 5(11): 12.doi:10.1371/journal.pbio.0050312
www.plosbiology.org

Source: Public Library of Science

Related stories:

A new century of Alzheimer's disease research
Imagine the day when a routine visit to the family doctor includes a simple blood test to predict the risk for developing Alzheimer’s disease (AD). If the test returns a worrisome result -- too many sticky brain proteins that might begin to gum up memory and thought in 10 to 15 years -- a person could be offered an aspirin-like pill to keep those proteins in check.
Scientists trace extensive networks regulating alternative RNA splicing
RNA targets of tissue-specific splicing factors Fox-1 and Fox-2 are successfully predicted
Two professors at Cold Spring Harbor Laboratory (CSHL) have succeeded in tracing intricate biochemical networks involving a class of proteins that enable genes to express themselves in specific tissues at particular moments in development.
New results help predict treatment response in colorectal cancer
Genetic testing can identify a group of patients with advanced colorectal cancer who are likely to survive on average twice as long if treated with the drug cetuximab, late breaking results show.
Designer RNA fights high cholesterol, researchers find
Small, specially designed bits of ribonucleic acid (RNA) can interfere with cholesterol metabolism, reducing harmful cholesterol by two-thirds in pre-clinical tests, according to a new study by researchers at UT Southwestern Medical Center in collaboration with Alnylam Pharmaceuticals and the Massachusetts Institute of Technology.
Natural selection may not produce the best organisms
"Survival of the fittest" is the catch phrase of evolution by natural selection. While natural selection favors the most fit organisms around, evolutionary biologists have long wondered whether this leads to the best possible organisms in the long run.
RNA emerges from DNA's shadow
RNA, the transporter of genetic information within the cell, has emerged from the shadow of DNA to become one of the hottest research areas of molecular biology, with implications for many diseases as well as understanding of evolution. But the field is complex, requiring access to the latest equipment and techniques of imaging, gene expression analysis and bioinformatics, as well as cross-pollination between multiple scientific disciplines. This has led to a major European push to bring the field together via a network of overlapping multidisciplinary projects, spearheaded by the European Science Foundation (ESF) with its EUROCORES Programme RNAQuality.
Blood vessel inhibitor shows promise against metastatic thyroid cancer
Thyroid cancer that has spread to distant sites has a poor prognosis, but an experimental drug that inhibits tumor blood vessel formation can slow disease progression in some patients, a research team led by investigators from The University of Texas M. D. Anderson Cancer Center reports in the July 3rd edition of The New England Journal of Medicine.
Gene mutation improves leukemia drug's effect
Gene mutations that make cells cancerous can sometimes also make them more sensitive to chemotherapy. A new study led by cancer researchers at Ohio State University shows that a mutation present in some cases of acute leukemia makes the disease more susceptible to high doses of a particular anticancer drug.

News discussion:

General Science news